Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

22.02 +0.60 (+2.80%)

Streaming Delayed Price Updated: 1:52 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	730,432
Open	21.05
Bid (Size)	22.00 (400)
Ask (Size)	22.04 (300)
Prev. Close	21.42
Today's Range	20.79 - 22.30
52wk Range	18.29 - 42.37
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Today 10:53 EDT

From Faruqi & Faruqi LLP

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

Today 10:32 EDT

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Performance

YTD	-6.7%	-6.7%
1 Month	-4.3%	-4.3%
3 Month	-4.3%	-4.3%
6 Month	-26.6%	-26.6%
1 Year	-34.9%	-34.9%

More News

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Today 10:24 EDT

From SkyMedia, LLC

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 10:17 EDT

From Schall Law

Via GlobeNewswire

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Today 8:30 EDT

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

April 01, 2026

From Berger Montague

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

March 31, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 30, 2026

From Schall Law

Via GlobeNewswire

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

March 30, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

March 25, 2026

From SkyMedia, LLC

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

March 25, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

March 25, 2026

From Robbins LLP

Via Business Wire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

March 24, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

RARE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

March 24, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

March 24, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 23, 2026

From Schall Law

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 20, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 19, 2026

From Schall Law

Via GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

March 18, 2026

From SkyMedia, LLC

Via GlobeNewswire

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

March 18, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

March 17, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 16, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 22.02

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 04/02/26 01:52 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.56B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.